Sherann Ivy
Psychiatric/Mental Health · Chicago, ILNPI 1467919498
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 352 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 28.4% of the total. Among psychiatric/mental health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Johnson & Johnson$524
- Otsuka America Pharmaceutical, Inc.$500
- Supernus Pharmaceuticals, Inc.$429
- Teva Pharmaceuticals USA, Inc.$408
- plus $2K from 14 others
What the payments were for
- Food & beverage$7,76499%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 76 | $2,233 |
| AbbVie | 110 | $1,900 |
| Johnson & Johnson | 27 | $524 |
| Otsuka America Pharmaceutical, Inc. | 23 | $500 |
| Supernus Pharmaceuticals, Inc. | 26 | $429 |
| Teva Pharmaceuticals USA, Inc. | 12 | $408 |
| Lundbeck LLC | 19 | $367 |
| Neurocrine Biosciences, Inc. | 9 | $306 |
| Alkermes, Inc. | 12 | $247 |
| Axsome Therapeutics, Inc. | 5 | $223 |
| Tris Pharma Inc | 4 | $179 |
| Indivior Inc. | 7 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $100 |
| Corium, LLC | 4 | $90 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Orexo US, Inc. | 3 | $45 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Noven Therapeutics, LLC | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$706
- AUSTEDO$125
- INGREZZA$122
- ABILIFY MAINTENA$118
- ABILIFY ASIMTUFII$118
- Dyanavel XR$115
- Auvelity$110
- Austedo XR$108
How this compares
$7,861 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Chlorpromazine Hcl | 56 | $4,890 |
| Divalproex Sodium | 55 | $2,204 |
| Quetiapine Fumarate | 60 | $1,084 |
| Clozapine | 28 | $961 |
| Alprazolam | 16 | $693 |
| Risperidone | 67 | $373 |
| Olanzapine | 64 | $366 |
| Benztropine Mesylate | 20 | $357 |
| Doxepin Hcl | 52 | $255 |
| Clonazepam | 44 | $238 |
| Aripiprazole | 12 | $198 |
| Prazosin Hcl | 12 | $170 |
| Bupropion Hcl SrBupropion Hcl | 12 | $96 |
| Sertraline Hcl | 14 | $89 |
| Citalopram HbrCitalopram Hydrobromide | 14 | $45 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Chicago
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$151K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Julie CarbrayChicago$36K
- Abigail HamiltonChicago$14K
- Anh NguyenChicago$9K
- Annabella Vidal-RuizChicago$8K
- Dina Pierre-GrayChicago$7K
- Natalia RysmanowskaChicago$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.